This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
VIDEO-Hepatitis C : Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127 and Ribavirin
Dr. Stefan Zeuzem discusses his manuscript "Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection."
No comments:
Post a Comment